Breast Cancer Study for Premenopausal Women with ER+/HER2-Breast Cancer.

ACCRU Trial Spotlight

Premenopausal women diagnosed with ER+/HER2- breast cancer tend to have a more aggressive form of disease compared to women diagnosed in the postmenopausal setting and as such are aggressively treated with chemotherapy, ovarian function suppression and aromatase inhibitors. While this therapeutic strategy improves breast cancer specific outcomes, it is associated with substantial morbidity. ACCRU Study ATOS-Z-201, conducted by study chair Dr. Matthew Goetz and his team, focuses on developing an alternative endocrine approach for premenopausal breast cancer patients using endoxifen without ovarian function suppression and aims to mechanistically understand the basis for endoxifen’s superior anticancer effects. For more information on the study, go here: